Piperlongumine inhibits gastric cancer cells via suppression of the JAK1,2/STAT3 signaling pathway

Song,Baoji; Zhan,Hongjie; Bian,Quan; Gu,Junping

doi:10.3892/mmr.2016.5091

Piperlongumine inhibits gastric cancer cells via suppression of the JAK1,2/STAT3 signaling pathway

Authors:
- Baoji Song
- Hongjie Zhan
- Quan Bian
- Junping Gu
View Affiliations

Affiliations: Department of General Surgery, Tianjin Hospital, Tianjin 300211, P.R. China, Department of Gastric Cancer, Tianjin Cancer Hospital, Key Laboratory of Cancer Prevention and Treatment of Tianjin, Tianjin Medical University, Tianjin 300060, P.R. China
Published online on: April 5, 2016 https://doi.org/10.3892/mmr.2016.5091
Pages: 4475-4480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Piperlongumine (PL), a major active component of long peppers, has been reported to possess anti‑cancer properties; however, its effect on gastric cancer (GC) has remained to be demonstrated. The present study assessed the effects of PL on the MKN45 and AGS GC cell lines and explored the underlying mechanisms. An MTT assay revealed that PL suppressed the proliferation of GC cells, while flow cytometric analysis showed that PL inhibited cell cycle progression. Furthermore, Transwell assays revealed the inhibitory effects of PL on the invasion and migration of GC cells. In addition, PL reduced the phosphorylation of Janus kinase (JAK)1, JAK2 and signal transducer and activator of transcription (STAT)3 in a concentration‑dependent manner, as indicated by western blot analysis, and decreased the expression of STAT3‑dependent tumor‑associated genes in GC cells, as revealed by PCR analysis. In conclusion, the present study was the first, to the best of our knowledge, to reveal the efficacy of PL against GC. The consumption of long peppers is therefore recommended for the prevention and treatment of GC, and PL may be a promising candidate drug for treating GC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C and Cervantes A: Unmet needs and challenges in gastric cancer: The way forward. Cancer Treat Rev. 40:692–700. 2014. View Article : Google Scholar : PubMed/NCBI
3	SR A, Cervantes A and van de Velde CJ: Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol. 14(Suppl 2): ii31–ii36. 2003.
4	Falcone A: Future strategies and adjuvant treatment of gastric cancer. Ann Oncol. 14(Suppl 2): ii45–ii47. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ang SD: Gastric cancer surgery: Can east meet west? J Surg Oncol. 102:7362010. View Article : Google Scholar : PubMed/NCBI
6	Krejs GJ: Gastric cancer: Epidemiology and risk factors. Dig Dis. 28:600–603. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li W, Qin J, Sun YH and Liu TS: Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis. World J Gastroenterol. 16:5621–5628. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, Kim WH, Lee KU and Yang HK: Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg. 98:255–260. 2011. View Article : Google Scholar
9	Park BS, Son DJ, Park YH, Kim TW and Lee SE: Antiplatelet effects of acidamides isolated from the fruits of Piper longum L. Phytomedicine. 14:853–855. 2007. View Article : Google Scholar : PubMed/NCBI
10	Yang YC, Lee SG, Lee HK, Kim MK, Lee SH and Lee HS: A piperidine amide extracted from Piper longum L. fruit shows activity against Aedes aegypti mosquito larvae. J Agr Food Chem. 50:3765–3767. 2002. View Article : Google Scholar
11	Son DJ, Kim SY, Han SS, Kim CW, Kumar S, Park BS, Lee SE, Yun YP, Jo H and Park YH: Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling. Biochem Bioph Res Commun. 427:349–354. 2012. View Article : Google Scholar
12	Bang JS, Oh da H, Choi HM, Sur BJ, Lim SJ, Kim JY, Yang HI, Yoo MC, Hahm DH and Kim KS: Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in rat arthritis models. Arthritis Res Ther. 11:R492009. View Article : Google Scholar : PubMed/NCBI
13	Fontenele JB, Leal L, Silveira ER, Felix FH, Bezerra Felipe CF and Viana GS: Antiplatelet effects of piplartine, an alkamide isolated from Piper tuberculatum: Possible involvement of cyclooxygenase blockade and antioxidant activity. J Pharm Pharmacol. 61:511–515. 2009. View Article : Google Scholar : PubMed/NCBI
14	Tsai IL, Lee FP, Wu CC, Duh CY, Ishikawa T, Chen JJ, Chen YC, Seki H and Chen IS: New cytotoxic cyclobutanoid amides, a new furanoid lignan and anti-platelet aggregation constituents from Piper arborescens. Planta Med. 71:535–542. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wakade AS, Shah AS, Kulkarni MP and Juvekar AR: Protective effect of Piper longum L. on oxidative stress induced injury and cellular abnormality in adriamycin induced cardiotoxicity in rats. Indian J Exp Biol. 46:528–533. 2008.PubMed/NCBI
16	Cícero Bezerra Felipe F, Trajano Sousa Filho J, de Oliveira Souza LE, Alexandre Silveira J, Esdras de Andrade Uchoa D, Rocha Silveira E, Deusdênia Loiola Pessoa O and de Barros Viana GS: Piplartine, an amide alkaloid from Piper tuberculatum, presents anxiolytic and antidepressant effects in mice. Phytomedicine. 14:605–612. 2007. View Article : Google Scholar : PubMed/NCBI
17	Vedhanayaki G, Shastri GV and Kuruvilla A: Analgesic activity of Piper longum Linn. root. Indian J Exp Biol. 41:649–651. 2003.
18	Randhawa H, Kibble K, Zeng H, Moyer M and Reindl K: Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro. 27:1626–1633. 2013. View Article : Google Scholar : PubMed/NCBI
19	Dhillon H, Chikara S and Reindl KM: Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol Rep. 1:309–318. 2014. View Article : Google Scholar : PubMed/NCBI
20	Gong LH, Chen XX, Wang H, Jiang QW, Pan SS, Qiu JG, Mei XL, Xue YQ, Qin WM and Zheng FY: Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev. 2014:9068042014. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Jackson C, Judd LM, Menheniott T, Kronborg I, Dow C, Yeomans ND, Boussioutas A, Robb L and Giraud A: Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J Pathol. 213:140–151. 2007. View Article : Google Scholar : PubMed/NCBI
23	Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
24	Heinrich P, Behrmann I, Haan S, Hermanns HM, Müller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
25	Böger C, Behrens HM and Röcken C: Ki67 - an unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity. J Surg Oncol. 113:46–54. 2016. View Article : Google Scholar
26	Wang Y, Zhou X, Shan B, Han J, Wang F, Fan X, Lv Y, Chang L and Liu W: Downregulation of microRNA-33a promotes cyclin dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation. Mol Med Rep. 12:6491–6500. 2015.PubMed/NCBI
27	Gao XH, Yang XQ, Wang BC, Liu SP and Wang FB: Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. Asian Pac J Cancer Prev. 14:5055–5060. 2013. View Article : Google Scholar : PubMed/NCBI
28	Jatiani SS, Baker SJ, Silverman LR and Reddy EP: JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies. Genes Cancer. 1:979–993. 2010. View Article : Google Scholar
29	Wu H, Huang M, Cao P, Wang T, Shu Y and Liu P: MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther. 13:281–288. 2012. View Article : Google Scholar : PubMed/NCBI
30	Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,2/STAT3 signaling induces apoptosis, cell cycle arrest and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
31	Ingley E and Klinken SP: Cross-regulation of JAK and Src kinases. Growth Factors. 24:89–95. 2006. View Article : Google Scholar : PubMed/NCBI
32	Akira S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene. 19:2607–2611. 2000. View Article : Google Scholar : PubMed/NCBI
33	Avalle L, Pensa S, Regis G, Novelli F and Poli V: STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT. 1:65–72. 2012.PubMed/NCBI
34	Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al: The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
35	Mukhopadhyay A1, Banerjee S, Stafford LJ, Xia C, Liu M and Aggarwal BB: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene. 21:8852–8861. 2002. View Article : Google Scholar : PubMed/NCBI
36	Weinstein IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis. 21:857–864. 2000. View Article : Google Scholar : PubMed/NCBI
37	Yu LF, Zhu YB, Qiao MM, Zhong J, Tu SP and Wu YL: Constitutive activation and clinical significance of Stat3 in human gastric cancer tissues and cell lines. Chin Med J. 84:2064–2069. 2004.In Chinese.
38	Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PloS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
39	Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: OPB–31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335:145–152. 2013. View Article : Google Scholar : PubMed/NCBI
40	Khanna P, Chua PJ, Bay BH and Baeg GH: The JAK/STAT signaling cascade in gastric carcinoma (Review). Int J Oncol. 47:1617–1626. 2015.PubMed/NCBI
41	Huang W, Yu LF, Zhong J, Wu W, Zhu JY, Jiang FX and Wu YL: Stat3 is involved in angiotensin II-induced expression of MMP2 in gastric cancer cells. Dig Dis Sci. 54:2056–2062. 2009. View Article : Google Scholar
42	Tactacan CM, Phua YW, Liu L, Zhang L, Humphrey ES, Cowley M, Pinese M, Biankin AV and Daly RJ: The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Mol Cancer. 14:139–149. 2015. View Article : Google Scholar : PubMed/NCBI